Matching articles for "Lamivudine"
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • August 26, 2019; (Issue 1579)
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI)...
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI) lamivudine
(Epivir, and generics), as a once-daily complete
regimen for treatment of adults with HIV-1 infection
who are antiretroviral-treatment naive and have no
known substitutions associated with resistance
to either drug. Dolutegravir/lamivudine is the first
complete regimen to be approved by the FDA for
initial treatment of HIV-1 infection that contains 2
rather than 3 antiretroviral drugs. Juluca, a fixed-dose
combination of dolutegravir and the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant), was approved in 2018 for treatment of
adults with HIV-1 infection already taking a stable,
suppressive antiretroviral regimen.
Symfi, Symfi Lo, and Cimduo for HIV (online only)
The Medical Letter on Drugs and Therapeutics • January 14, 2019; (Issue 1563)
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor...
The FDA has approved three new once-daily fixed-dose
antiretroviral drug combinations for treatment of HIV-1 infection. Symfi and Symfi Lo (Mylan) contain the
non-nucleoside reverse transcriptase inhibitor (NNRTI)
efavirenz and the nucleoside reverse transcriptase
inhibitors (NRTIs) lamivudine and tenofovir disoproxil
fumarate (TDF) and were approved as complete
antiretroviral regimens. Symfi Lo contains a lower
dose of efavirenz than both Symfi and Atripla, a fixed-dose
combination of efavirenz, TDF, and the NRTI
emtricitabine that was approved in 2006. Cimduo
(Mylan), which contains lamivudine and TDF, was
approved for use in combination with other antiretroviral
drugs. All three new products are marketed as less
expensive alternatives to other available fixed-dose
antiretroviral combinations (see Table 1).
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs)...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the combination.
Genvoya - A New 4-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • February 15, 2016; (Issue 1488)
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the...
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first
approval for tenofovir alafenamide (TAF), a tenofovir
prodrug. Stribild, a fixed-dose combination of
elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate (TDF), was approved in 2012.
Elvitegravir (Vitekta) for HIV
The Medical Letter on Drugs and Therapeutics • January 18, 2016; (Issue 1486)
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of...
The FDA has approved elvitegravir (Vitekta – Gilead),
an integrase strand transfer inhibitor (INSTI), for use
with a protease inhibitor (PI) plus ritonavir and other
antiretroviral drugs for treatment of HIV-1 infection
in treatment-experienced adults. Elvitegravir is also
available in a fixed-dose combination (Stribild) with
the pharmacokinetic enhancer cobicistat and the
nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs) emtricitabine and tenofovir disoproxil
fumarate (DF). A similar combination (Genvoya) that
includes tenofovir alafenamide instead of tenofovir DF
was recently approved by the FDA and will be reviewed
in a future issue.
Triumeq: A 3-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • January 5, 2015; (Issue 1459)
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir...
The FDA has approved Triumeq (Viiv Healthcare),
a fixed-dose combination of the integrase strand
transfer inhibitor (INSTI) dolutegravir and the
nucleoside reverse transcriptase inhibitors (NRTIs)
abacavir and lamivudine, for once-daily treatment of
HIV-1 infection. Dolutegravir (Tivicay) was approved
as a single agent in 2013.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2014; (Issue 138)
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Antiviral Drugs
The Medical Letter on Drugs and Therapeutics • March 1, 2013; (Issue 127)
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • June 1, 2011; (Issue 106)
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is...
Guidelines for use of antiretroviral agents continue to shift toward earlier and more continuous treatment, both to treat the patient and to prevent transmission of the disease to others. Resistance testing is now recommended when antiretroviral drugs are started. Increases in HIV RNA levels ("viral load") while on therapy may indicate development of drug resistance, requiring further testing and a change in the treatment regimen. Antiretroviral drugs interact with each other and with many other drugs; complete information on these interactions is available at www.aidsinfo.nih.gov.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2010; (Issue 98)
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been...
The drugs of choice for treatment of non-HIV viral
infections and their dosages are listed in Tables 1-6 on
the pages that follow. Some of the indications and
dosages recommended here have not been approved
by the FDA. Vaccines used for the prevention of viral
infections are discussed in another issue of Treatment
Guidelines.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • February 1, 2009; (Issue 78)
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on...
New guidelines for use of antiretroviral agents have been published, with a shift towards earlier and more continuous treatment. HIV infection is treated with combinations of antiretroviral drugs depending on the patientÆs HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance, requiring further testing and a change in treatment regimen. Resistance testing is now recommended when a patient is first seen, regardless of when therapy will be started.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • September 1, 2007; (Issue 61)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2007; (Issue 59)
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA....
The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the "Adult Immunization" issue of Treatment Guidelines.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • October 1, 2006; (Issue 50)
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral...
The approval of new drugs and continuing concerns about drug toxicity and resistance have prompted new antiretroviral treatment guidelines. Resistance testing is not recommended before starting antiretroviral therapy. HIV infection is treated with combinations of antiretroviral drugs while monitoring the patient's HIV RNA levels ("viral load") and CD4 cell count. Increases in viral load while on therapy may indicate development of drug resistance requiring further testing and a change in treatment regimen.
Entecavir (Baraclude) for Chronic Hepatitis B
The Medical Letter on Drugs and Therapeutics • June 6, 2005; (Issue 1210)
Entecavir (Baraclude - Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV)...
Entecavir (Baraclude - Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV) infection.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • April 1, 2005; (Issue 32)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the FDA.
Two Once-Daily Fixed-Dose NRTI Combinations for HIV
The Medical Letter on Drugs and Therapeutics • February 28, 2005; (Issue 1203)
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for...
The FDA has approved emtricitabine/tenofovir (Truvada - Gilead) and abacavir/lamivudine (Epzicom - GSK), two new fixed-dose combinations of nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), for once-daily use in treatment of HIV infection. Two other fixed-dose NRTI combinations were previously approved for twice-daily dosing. Dual NRTI therapy is generally used in either an NNRTI (non-nucleoside reverse transcriptase inhibitor)-based or a PI (protease inhibitor)-based regimen.
Drugs for Sexually Transmitted Infections
The Medical Letter on Drugs and Therapeutics • October 1, 2004; (Issue 26)
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric...
Many infections can be transmitted during sexual contact. The text and tables that follow are limited to management of sexually transmitted infections (STIs) other than HIV, viral hepatitis and enteric infections. Guidelines are available from the US Centers for Disease Control and Prevention (CDC) with detailed recommendations for treatment of these diseases (MMWR Recomm Rep 2002; 51, RR-6:1). New guidelines are expected soon.
Drugs for HIV
The Medical Letter on Drugs and Therapeutics • January 1, 2004; (Issue 17)
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV...
New drug approvals as well as continuing concerns about drug toxicity and the development of resistance have prompted new antiretroviral treatment guidelines (Panel on Clinical Practices for Treatment of HIV Infection, November 10, 2003, www.aidsinfo.nih.gov).
Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection
The Medical Letter on Drugs and Therapeutics • November 10, 2003; (Issue 1169)
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine,...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Adefovir (Hepsera) for Chronic Hepatitis B Infection
The Medical Letter on Drugs and Therapeutics • December 9, 2002; (Issue 1145)
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal...
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity, the FDA rejected a higher-dosage formulation of adefovir for treatment of HIV infection.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • February 4, 2002; (Issue 1123)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some new recommendations for old drugs have been added.
Drugs for HIV
The Medical Letter on Drugs and Therapeutics • November 26, 2001; (Issue 1119)
Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs...
Since the last Medical Letter article on this subject, continuing concerns about drug toxicity and development of resistance have prompted new antiretroviral treatment guidelines. The dosage and cost of drugs for HIV infection are listed in the table in this article.
Lopinavir/Ritonavir: A Protease-inhibitor Combination
The Medical Letter on Drugs and Therapeutics • January 8, 2001; (Issue 1095)
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more...
Lopinavir/ritonavir is the first fixed-dose combination of protease inhibitors approved by the FDA for the treatment of HIV infection. It is being marketed for use with other drugs in adults and children more than six months old. Lopinavir is a new drug available only in this combination. Ritonavir is often used with other protease inhibitors to raise their plasma concentrations.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • January 10, 2000; (Issue 1069)
Highly active anti-retroviral therapy (HAART) combining three or four drugs has become the standard of care for treatment of human immunodeficiency virus (HIV)...
Highly active anti-retroviral therapy (HAART) combining three or four drugs has become the standard of care for treatment of human immunodeficiency virus (HIV) infection
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • December 3, 1999; (Issue 1067)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's]...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.
Amprenavir: A New HIV Protease Inhibitor
The Medical Letter on Drugs and Therapeutics • July 16, 1999; (Issue 1057)
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least...
Amprenavir is the fifth protease inhibitor to become available for treatment of HIV infection. It was approved by the FDA for use with other drugs in the treatment of HIV-infected adults and children at least four years old.
Three New Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • December 4, 1998; (Issue 1041)
Combination antiretroviral therapy including protease inhibitors has dramatically changed the treatment of HIV infection and the prognosis of those affected (Medical Letter Handbook of Antimicrobial Therapy,...
Combination antiretroviral therapy including protease inhibitors has dramatically changed the treatment of HIV infection and the prognosis of those affected (Medical Letter Handbook of Antimicrobial Therapy, 1998, page 122). Due to limitations and failures with these drugs in many patients, however, three new drugs, none of them protease inhibitors, have rapidly come into wide use in clinical trials or 'expanded access' programs. They are abacavir (Ziagen - Glaxo Wellcome), adefovir (Preveon - Gilead) and efavirenz (Sustiva - DuPont). Efavirenz was recently approved for treatment of adults and children by the FDA. Abacavir has been recommended for approval by an FDA advisory committee.
Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • December 5, 1997; (Issue 1015)
Recent studies have led to changes in the approach to treating human immunodeficiency virus (HIV) infection (CCJ Carpenter et al, JAMA, 277:1962, 1997). None of the drugs currently available to treat...
Recent studies have led to changes in the approach to treating human immunodeficiency virus (HIV) infection (CCJ Carpenter et al, JAMA, 277:1962, 1997). None of the drugs currently available to treat HIV-infected patients has been shown to eradicate the infection, but used in combination they can decrease viral replication, improve immunologic status, delay infectious complications and prolong life. The drug regimens recommended by Medical Letter consultants are listed in the table on page 114. Adult regimens and dosages may not be applicable to children (Guidelines for use of Antiretroviral Agents in Pediatric HIV Infection, HIV/AIDS Treatment Information Services, www.hivatis.org/glarvped.html). Some drugs interactions of anti-HIV drugs are listed on the table that begins on page 115.
Drugs for Non-HIV Viral Infections
The Medical Letter on Drugs and Therapeutics • August 1, 1997; (Issue 1006)
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future...
The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.
More New Drugs for HIV and Associated Infections
The Medical Letter on Drugs and Therapeutics • February 14, 1997; (Issue 994)
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine (Viramune - Roxane), intravenous cidofovir (Vistide - Gilead), and amphotericin B oral suspension (Fungizone...
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine (Viramune - Roxane), intravenous cidofovir (Vistide - Gilead), and amphotericin B oral suspension (Fungizone Oral Suspension - Bristol-Myers Squibb) have been approved by the US Food and Drug Administration; nelfinavir (Viracept - Agouron) is currently available only through an "Expanded Access Program."
New Drugs for HIV Infection
The Medical Letter on Drugs and Therapeutics • April 12, 1996; (Issue 972)
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo...
The US Food and Drug Administration (FDA) has approved the marketing of five new drugs for treatment of HIV Infection. Stavudine (D4T; Zerit - Bristol-Myers Squibb) and lamivudine (3TC; Epivir - Glaxo Wellcome) are nucleoside analogs similar to zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). Saquinavir (Invirase - Roche), ritonavir (Norvir - Abbott) and indinavir (Crixivan - Merck) are protease inhibitors, a new class of anti-HIV drugs.
Drugs for AIDS and Associated Infections
The Medical Letter on Drugs and Therapeutics • October 13, 1995; (Issue 959)
Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with...
Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.